Leslie J. Holsinger
Plus aucun poste en cours
Fortune : 3 710 $ au 31/03/2024
Profil
Leslie J.
Holsinger worked as a Group Leader at Sugen, Inc. and as the Head of Cell Biology Division at Celera Group.
Later, she worked as the Vice President of Biology at Virobay, Inc. from 2011 to 2016.
Currently, she is the Executive Vice President of Research and Development at Quince Therapeutics, Inc. since 2020.
Holsinger holds a doctorate from Northwestern University and an undergraduate degree from Occidental College.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 31/03/2023 | 3 500 ( 0,01% ) | 3 710 $ | 31/03/2024 |
Anciens postes connus de Leslie J. Holsinger
| Sociétés | Poste | Fin |
|---|---|---|
| QUINCE THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 31/07/2022 |
Virobay, Inc.
 Virobay, Inc. Pharmaceuticals: MajorHealth Technology Virobay, Inc. develops protease inhibitors for the treatment of neuropathic pain, cancer, autoimmune and liver diseases. It utilize cysteine cathepsin platform for the development and commercialization of novel drugs. The firm's research & development activities focuses on neuropathic pain, autoimmune diseases and liver fibrosis. The company was founded by Robert F. G. Booth on May 18, 2006 and is headquartered in Menlo Park, CA. | Corporate Officer/Principal | 01/01/2016 |
Celera Group
 Celera Group Pharmaceuticals: MajorHealth Technology Celera Group provides molecular diagnostics using proprietary genomics and proteomics discovery platforms to identify and validate novel diagnostic markers and to develop diagnostic products based on these markers. These diagnostic products are used to predict disease risk and optimize therapy selection, monitoring and patient outcome. The company was founded in May, 1998 and is located in Rockville, MD | Corporate Officer/Principal | - |
Sugen, Inc.
 Sugen, Inc. Pharmaceuticals: MajorHealth Technology Sugen, Inc. developed small molecule drugs and related pharmaceutical products. The company was founded on July 1, 1991 and was headquartered in New York, NY. | Corporate Officer/Principal | - |
Formation de Leslie J. Holsinger
| Northwestern University | Doctorate Degree |
| Occidental College | Undergraduate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 4 |
|---|---|
Sugen, Inc.
Sugen, Inc. Pharmaceuticals: MajorHealth Technology Sugen, Inc. developed small molecule drugs and related pharmaceutical products. The company was founded on July 1, 1991 and was headquartered in New York, NY. | Health Technology |
Virobay, Inc.
Virobay, Inc. Pharmaceuticals: MajorHealth Technology Virobay, Inc. develops protease inhibitors for the treatment of neuropathic pain, cancer, autoimmune and liver diseases. It utilize cysteine cathepsin platform for the development and commercialization of novel drugs. The firm's research & development activities focuses on neuropathic pain, autoimmune diseases and liver fibrosis. The company was founded by Robert F. G. Booth on May 18, 2006 and is headquartered in Menlo Park, CA. | Health Technology |
Celera Group
Celera Group Pharmaceuticals: MajorHealth Technology Celera Group provides molecular diagnostics using proprietary genomics and proteomics discovery platforms to identify and validate novel diagnostic markers and to develop diagnostic products based on these markers. These diagnostic products are used to predict disease risk and optimize therapy selection, monitoring and patient outcome. The company was founded in May, 1998 and is located in Rockville, MD | Health Technology |
| Quince Therapeutics, Inc. |
